FIELD: medicine; pharmaceuticals.
SUBSTANCE: group of inventions refers to an agent for suppression of progression, suppression of recurrence and/or treatment of a malignant growth. Disclosed is the use of the anti-allergin-1 antibody for improving immunity against a malignant growth in a patient with a solid malignant growth. Also disclosed is a method of increasing immunity against a solid malignant neoplasm and using the anti-allergin-1 antibody in preparing an agent increasing immunity for treating a solid malignant growth.
EFFECT: group of inventions provides higher immunity against a malignant growth.
27 cl, 14 dwg, 1 tbl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES AGAINST PD-1 FOR TREATMENT OF LUNG CANCER | 2018 |
|
RU2771759C2 |
| COMPOSITION FOR PREVENTING OR TREATING MALIGNANT TUMOUR, COMPRISING AGENT DESTROYING VESSELS, AND IMMUNE CONTROL POINT INHIBITOR | 2018 |
|
RU2738369C1 |
| COMBINED METHODS FOR TREATING WITH PD-L1 ANTAGONISTS | 2016 |
|
RU2766890C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATING MALIGNANT NEOPLASM | 2018 |
|
RU2730984C1 |
| HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR PROGRAMMED CELL DEATH 1 (PD1) PROTEIN AND METHODS OF TREATING CANCER WITH USING ANTI-PD1 ANTIBODIES EITHER INDIVIDUALLY, OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTIC AGENTS | 2006 |
|
RU2494107C2 |
| NICOTINYL ALCOHOL ETHER DERIVATIVE MALEATE, ITS CRYSTALLINE FORM AND ITS USE | 2020 |
|
RU2816099C1 |
| METHOD FOR IMPROVING IMMUNE CELL FUNCTION AND EVALUATING MULTIFUNCTIONALITY OF IMMUNE CELLS | 2015 |
|
RU2731098C2 |
| HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED DEATH 1 (PD-1) PROTEIN AND CANCER TREATMENT METHOD USING ANTI-PD-1-ANTIBODIES SEPARATELY OR COMBINED WITH OTHER IMMUNOTHERAPEUTIC AGENTS | 2013 |
|
RU2599417C2 |
| TREATING CANCER WITH COMBINATION OF PD-1 ANTAGONIST AND DINACICLIB | 2014 |
|
RU2705795C2 |
| ANTITUMOR AGENT AND ANTITUMOR EFFECT AMPLIFIER | 2018 |
|
RU2783759C2 |
